Non-cytomegalovirus ocular opportunistic infections in patients with AIDS Sapna Gangaputra 1 , Lea Drye 2 , Vijay Vaidya 2 , Jennifer E. Thorne 2,3 , Douglas A Jabs 2,4,5 , and Alice T. Lyon 6 for the Studies of the Ocular Complications of AIDS (SOCA) Research Group 1 Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, WI 2 Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 3 Department of Ophthalmology, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, MD 4 Department of Ophthalmology, The Mount Sinai School of Medicine, New York, NY 5 Department of Medicine, The Mount Sinai School of Medicine, New York, NY 6 Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL Abstract Purpose—To report the incidence and clinical outcomes of non-cytomegalovirus (non-CMV) ocular opportunistic infections in patients with AIDS in the era of highly active antiretroviral therapy (HAART). Design—Multicenter, prospective, observational study of patients with AIDS Methods—Medical history, ophthalmologic examination, and laboratory tests were performed at enrollment and every 6 months subsequently. Once an ocular opportunistic infection was diagnosed, patients were seen every 3 months for outcomes. Results—At enrollment, 37 non-CMV ocular opportunistic infections were diagnosed: 16 patients, herpetic retinitis; 11 patients, toxoplasmic retinitis; and 10 patients, choroiditis. During Corresponding Author: Alice Lyon, MD, Director, Vitreoretinal Service, Northwestern University Feinberg School of Medicine, 645 North Michigan Avenue, Suite 440, Chicago, IL 60611, Phone: 312-908-8152 Fax: 312-503-8152 a-lyon@northwestern.edu. Financial Disclosures: Dr Thorne is the recipient of a Research to Prevent Blindness (RPB) Sybil B. Harrington Special Scholars Award. Dr Jabs serves as a member of the board for Applied Genetic Technologies and Novartis Pharmaceuticals Corporation and as a consultant for the following: Abbott Laboratories, Alcon Laboratories, Allergan Pharmaceutical Corporation, Corcept Therapeutics, GenenTech, Genzyme Corporation, GlaxoSmithKline, and Roche Pharmaceuticals. Dr Thorne serves on a scientific advisory board for Allergan, Inc. and has been a consultant for Heron Evidence Development Ltd and XOMA. All other authors have no financial disclosures to report. Contributions to Authors in each of these areas: Design of the study (SG, LD, VV, JET, DAJ, ATL, SOCA Research Group); Conduct of the study (SG, LD, VV, JET, ATL, SOCA Research Group); Collection of data (SOCA Research Group); Management of data (SG, LD, VV, JET, SOCA Research Group); Analysis of data (LD, VV); Interpretation of data (SG, LD, VV, JET, DAJ, ATL); Preparation of manuscript (SG, LD, VV, JET, DAJ, ATL); Review of manuscript (SG, LD, VV, JET, DAJ, ATL). NIH Public Access Author Manuscript Am J Ophthalmol. Author manuscript; available in PMC 2014 September 15. Published in final edited form as: Am J Ophthalmol. 2013 February ; 155(2): 206–212.e5. doi:10.1016/j.ajo.2012.07.019. NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript